Suppr超能文献

地塞米松:在 COVID-19 大流行期间的治疗潜力、风险和未来展望。

Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.

机构信息

Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, 63100, Punjab, Pakistan.

出版信息

Eur J Pharmacol. 2021 Mar 5;894:173854. doi: 10.1016/j.ejphar.2021.173854. Epub 2021 Jan 8.

Abstract

The current outbreak of novel COVID-19 challenges the development of an efficient treatment plan as soon as possible. Several promising treatment options stand out as potential therapy of COVID-19, including plasma-derived drugs, monoclonal antibodies, antivirals, antimalarial, cell therapy, and corticosteroids. Dexamethasone an approved corticosteroid medication, acting as an anti-inflammatory and immunosuppressant agent. In the current pandemic, dexamethasone is declared a "major development" in the fight against COVID-19. Steroidal dexamethasone was presented as the recent advancement that significantly reduces the mortality rate among severe COVID-19 cases. This review summarizes the preliminary opinion about the dexamethasone outbreak, therapeutic potential, risks, and strategies during the COVID-19 pandemic.

摘要

目前新型 COVID-19 的爆发对尽快制定有效的治疗方案提出了挑战。有几种有前途的治疗选择被突出为 COVID-19 的潜在治疗方法,包括血浆衍生药物、单克隆抗体、抗病毒药物、抗疟药物、细胞疗法和皮质类固醇。地塞米松是一种已批准的皮质类固醇药物,具有抗炎和免疫抑制作用。在当前的大流行中,地塞米松被宣布为对抗 COVID-19 的“重大进展”。甾体地塞米松被认为是最近的一项进展,它显著降低了重症 COVID-19 病例的死亡率。这篇综述总结了关于 COVID-19 大流行期间地塞米松爆发、治疗潜力、风险和策略的初步意见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd35/7836247/6087a22ae58e/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验